FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034553410> ?p ?o ?g. }

• W2034553410 abstract "Background Erythropoiesis stimulating agents (ESAs) has been shown to be highly effective in anaemia in chronic kidney disease (CKD). Various biological ESAs are available such as epoetin alfa, beta, darbepoetin alfa and C.E.R.A, including three biosimilars, epoetin alfa, zeta and theta. National regulations are trying to promote the prescription of the biosimilars, especially in ESA-naive patients. Switching between products is not recommended and the pharmacist can’t replace one epoetin with another. However, changes do occur in clinical practise. Purpose In the Pharmacy Department of the Palermo Local Health Unit (LHU) we observed that nephrologists frequently switch patients but not in order to reduce costs. Therefore, the aim of this study was to calculate the prevalence and patterns of switching and to evaluate the reasons for them and the results for these changes. Materials and Methods Distributing all the epoetins, after a discharge or a DH (docetaxel/trastuzumab) regimen and ensuring appropriate continuity of care, the Department collected and retrospectively analysed an electronic database with all the prescriptions for both non-dialysis-dependent CKD or dialysis patients. Furthermore, haemoglobin levels (Hb) were collected, if available, from the paper prescriptions. The period of observations was January 2011–June 2012. Results 2,711 patients received an epoetin for CKD (from a population of 750,550). 368 patients (13.6%) had been switched. Of this group, only 194 patients were evaluable (98 female, mean age 73.57+-SD:14.21). The inclusion criteria were: receiving ESAs for at least four months; less than 60 days between two prescriptions. Treatments were less commonly switched from biosimilars than originator formulations. Only in 7 cases did nephrologists cite the lack of efficacy of the ESA previously administered, with demonstrated worsening of the patient’s clinical status (Aranesp 4, Mircera 2 and NeoRecormon 1). In 9 cases we assumed lack of efficacy of the first ESA, based on measurement of the haemoglobin (Hb) values. In the following prescription the clinicians switched and reported an Hb level lower than the first (≤10 g/L). In 24 cases, the ESAs varied with the prescriber. There was no reason for the switch or it was made for trivial reasons. 5 changes from the biosimilar were the pharmacist’s wrong decision, due to not checking the patient’s last prescription on the database. 5 changes from Mircera occurred after the announcement of a worldwide shortage. Only in 9 cases had the clinicians decided to shift toward a biosimilar on cost grounds. In the remaining cases, Hb levels remained stable before and after the switch. We can also state that no spontaneous reports of adverse drug reactions regarding ESAs have been received. Conclusions Our results demonstrates that all the switches were well tolerated. This may support the use of biosimilars in terms of safety and efficacy and switches towards less expensive epoetins. The decision to start ESA treatment with a biosimilar must be considered, and it will also be possible to change pretreated patients. No conflict of interest." @default.
• W2034553410 created "2016-06-24" @default.
• W2034553410 creator A5073729414 @default.
• W2034553410 creator A5083038373 @default.
• W2034553410 date "2013-03-01" @default.
• W2034553410 modified "2023-09-24" @default.
• W2034553410 title "CPC-003 A Retrospective Analysis of the Switches from Originator and Biosimilar Recombinant Human Erythropoietins in Chronic Kidney Disease" @default.
• W2034553410 doi "https://doi.org/10.1136/ejhpharm-2013-000276.460" @default.
• W2034553410 hasPublicationYear "2013" @default.
• W2034553410 type Work @default.
• W2034553410 sameAs 2034553410 @default.
• W2034553410 citedByCount "0" @default.
• W2034553410 crossrefType "journal-article" @default.
• W2034553410 hasAuthorship W2034553410A5073729414 @default.
• W2034553410 hasAuthorship W2034553410A5083038373 @default.
• W2034553410 hasBestOaLocation W20345534101 @default.
• W2034553410 hasConcept C104863432 @default.
• W2034553410 hasConcept C126322002 @default.
• W2034553410 hasConcept C177713679 @default.
• W2034553410 hasConcept C2426938 @default.
• W2034553410 hasConcept C2776164570 @default.
• W2034553410 hasConcept C2778534260 @default.
• W2034553410 hasConcept C2778653478 @default.
• W2034553410 hasConcept C2779457091 @default.
• W2034553410 hasConcept C2908647359 @default.
• W2034553410 hasConcept C512399662 @default.
• W2034553410 hasConcept C59491497 @default.
• W2034553410 hasConcept C71924100 @default.
• W2034553410 hasConcept C98274493 @default.
• W2034553410 hasConcept C99454951 @default.
• W2034553410 hasConceptScore W2034553410C104863432 @default.
• W2034553410 hasConceptScore W2034553410C126322002 @default.
• W2034553410 hasConceptScore W2034553410C177713679 @default.
• W2034553410 hasConceptScore W2034553410C2426938 @default.
• W2034553410 hasConceptScore W2034553410C2776164570 @default.
• W2034553410 hasConceptScore W2034553410C2778534260 @default.
• W2034553410 hasConceptScore W2034553410C2778653478 @default.
• W2034553410 hasConceptScore W2034553410C2779457091 @default.
• W2034553410 hasConceptScore W2034553410C2908647359 @default.
• W2034553410 hasConceptScore W2034553410C512399662 @default.
• W2034553410 hasConceptScore W2034553410C59491497 @default.
• W2034553410 hasConceptScore W2034553410C71924100 @default.
• W2034553410 hasConceptScore W2034553410C98274493 @default.
• W2034553410 hasConceptScore W2034553410C99454951 @default.
• W2034553410 hasLocation W20345534101 @default.
• W2034553410 hasOpenAccess W2034553410 @default.
• W2034553410 hasPrimaryLocation W20345534101 @default.
• W2034553410 hasRelatedWork W1968553893 @default.
• W2034553410 hasRelatedWork W1973010036 @default.
• W2034553410 hasRelatedWork W2022953798 @default.
• W2034553410 hasRelatedWork W2033803279 @default.
• W2034553410 hasRelatedWork W2034418975 @default.
• W2034553410 hasRelatedWork W2082040887 @default.
• W2034553410 hasRelatedWork W2090652903 @default.
• W2034553410 hasRelatedWork W2097784182 @default.
• W2034553410 hasRelatedWork W2113406202 @default.
• W2034553410 hasRelatedWork W2118564242 @default.
• W2034553410 hasRelatedWork W2755032674 @default.
• W2034553410 hasRelatedWork W2756268363 @default.
• W2034553410 hasRelatedWork W2900492801 @default.
• W2034553410 hasRelatedWork W2910600549 @default.
• W2034553410 hasRelatedWork W2941651537 @default.
• W2034553410 hasRelatedWork W2949158128 @default.
• W2034553410 hasRelatedWork W2979546325 @default.
• W2034553410 hasRelatedWork W2980288663 @default.
• W2034553410 hasRelatedWork W3017093286 @default.
• W2034553410 hasRelatedWork W3017142112 @default.
• W2034553410 isParatext "false" @default.
• W2034553410 isRetracted "false" @default.
• W2034553410 magId "2034553410" @default.
• W2034553410 workType "article" @default.